Business Context and Reporting Period
This Form 8-K Current Report was filed by Processa Pharmaceuticals, Inc. on June 19, 2019. The filing documents the results of the company's Annual Meeting of Stockholders held on the same date. Processa is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance actions and stockholder voting results.
Material Changes and Corporate Actions
- Approval of New Equity Plan: Stockholders approved the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan. This plan reserves an aggregate maximum of 3,500,000 shares of Common Stock for issuance to eligible employees, directors, and consultants.
- Termination of Prior Plan: Simultaneously with the new plan's approval, the Heatwurx, Inc. 2011 Amended and Restated Equity Plan was terminated. No new awards will be granted under the prior plan, though outstanding awards remain valid.
- Director Elections: Stockholders elected four directors: David Young, Pharm.D., Ph.D.; Patrick Lin; Justin Yorke; and Virgil Thompson.
- Accounting Firm Ratification: Stockholders ratified the selection of BD & Company Inc. as the independent registered public accounting firm for the fiscal year ending December 31, 2019.
Voting Results Summary
| Proposal | For | Against | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| Election of Directors (All 4 Nominees) | 36,219,738 | 58,041 | 0 | 362,760 |
| 2019 Omnibus Incentive Plan | 36,218,717 | 47,027 | 12,035 | 362,760 |
| Ratification of Auditor | 36,628,525 | 1,000 | 11,014 | N/A |
Total shares entitled to vote were 38,674,265. Shares present in person or by proxy were 36,640,539.
Guidance, Outlook, and Risks
The filing does not provide management commentary on financial guidance, future outlook, or specific risk factors. The document serves as a procedural record of the Annual Meeting outcomes.
Key Facts for Investor Verification
- Verify the specific terms and vesting schedules of the newly approved 2019 Omnibus Incentive Plan (3.5 million share reserve) in the referenced Proxy Statement.
- Confirm the status of outstanding awards under the terminated Heatwurx, Inc. 2011 Plan to assess potential future dilution.
- Note the high level of support for the new incentive plan and director elections, with over 99% of votes cast in favor of the proposals.
- Review the definitive proxy statement filed on April 26, 2019, for detailed descriptions of the incentive plan and director biographies.